Peripheral T Cell Lymphoma Clinical Trials

43 recruiting

Frequently Asked Questions

Common questions about Peripheral T Cell Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 45 trials

Recruiting
Phase 1

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedPeripheral T Cell LymphomaRelapsed Peripheral T-Cell Lymphoma+4 more
Mayo Clinic21 enrolled2 locationsNCT06508463
Recruiting

T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR

Peripheral T Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine58 enrolled1 locationNCT07470996
Recruiting
Phase 3

Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy

Peripheral T Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine68 enrolled1 locationNCT07414758
Recruiting
Phase 1

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

Peripheral T Cell LymphomaAnaplastic Large Cell LymphomaMycosis Fungoides+7 more
National Cancer Institute (NCI)60 enrolled1 locationNCT07055477
Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Diffuse Large B Cell LymphomaHodgkin LymphomaNon-Hodgkin Lymphoma+16 more
Children's Hospital Medical Center, Cincinnati30 enrolled5 locationsNCT06131801
Recruiting
Phase 2

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

Peripheral T Cell Lymphoma
M.D. Anderson Cancer Center30 enrolled1 locationNCT06630091
Recruiting
Phase 2Phase 3

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

Peripheral T Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine40 enrolled1 locationNCT07389616
Recruiting
Phase 1Phase 2

Evaluate the Safety and Clinical Activity of HH2853

Advanced Solid TumorPeripheral T Cell LymphomaFL Lymphoma+1 more
Haihe Biopharma Co., Ltd.254 enrolled25 locationsNCT04390737
Recruiting
Phase 2

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

T-cell LymphomaT-cell Prolymphocytic LeukemiaLymphoma, T-Cell+5 more
Jonathan Brammer44 enrolled1 locationNCT07356245
Recruiting

T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR

Peripheral T Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine160 enrolled1 locationNCT07353840
Recruiting
Phase 2

Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Relapsed/Refractory Peripheral T Cell Lymphoma
Fudan University25 enrolled1 locationNCT06519526
Recruiting
Phase 3

A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Relapsed/Refractory Peripheral T Cell Lymphoma
Evopoint Biosciences Inc.120 enrolled1 locationNCT06776952
Recruiting
Phase 1Phase 2

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Peripheral T Cell Lymphoma
Sun Yat-sen University101 enrolled1 locationNCT07093710
Recruiting

Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR)

Peripheral T Cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine88 enrolled1 locationNCT07253129
Recruiting
Phase 1Phase 2

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Acute Myeloid LeukemiaNon-Hodgkin LymphomaMultiple Myeloma+3 more
CellCentric Ltd.250 enrolled39 locationsNCT04068597
Recruiting
Phase 2

Amping up With PemJAK

Non-Hodgkin LymphomaPeripheral T Cell LymphomaPrimary Mediastinal B Cell Lymphoma+5 more
Seda S. Tolu53 enrolled1 locationNCT07283822
Recruiting
Phase 1Phase 2

Linperlisib Combined With Chidamide in Patients With PTCL

Peripheral T Cell Lymphoma
Yanyan Liu134 enrolled6 locationsNCT06421948
Recruiting

Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study

Peripheral T Cell Lymphoma
Fudan University3,000 enrolled1 locationNCT07270861
Recruiting
Phase 3

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

Peripheral T Cell Lymphoma
Dizal Pharmaceuticals218 enrolled50 locationsNCT07234162
Recruiting
Phase 1

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Hodgkin LymphomaNon-Hodgkin LymphomaPeripheral T Cell Lymphoma+4 more
Baylor College of Medicine90 enrolled2 locationsNCT06176690